ArticleInternational journal of women's health2026
Erythrocyte Folate and Homocysteine in Hypertensive Disorders of Pregnancy: Associations with Pregnancy Outcomes.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertensive disorders complicating pregnancy (HDCP) are a major cause of maternal and fetal morbidity. This study aims to examine the relationship between red blood cell folate (RBCF) and homocysteine (Hcy) levels and HDCP severity, as well as to assess their predictive value for pregnancy outcomes. Methods: This retrospective study included 326 HDCP patients and 153 controls. The diagnostic criteria for HDCP were based on the American College of Obstetricians and Gynecologists. RBCF and Hcy levels were measured at diagnosis using automated immunoassays. ROC curve analysis was performed to assess the predictive value of RBCF and Hcy for poor pregnancy outcomes. Results: A total of 326 women with HDCP and 153 normotensive controls were included. Blood pressure was significantly higher in the HDCP group (both p < 0.001). HDCP patients exhibited markedly lower RBC folate (286.08 ± 59.04 vs 334.83 ± 51.95 ng/mL, p < 0.001) and higher Hcy levels (8.41 ± 1.39 vs 7.58 ± 1.40 μmol/L, p < 0.001) than controls. Across HDCP severity, RBCF declined progressively from gestational hypertension to mild and severe preeclampsia, while Hcy increased correspondingly. Among HDCP patients, adverse pregnancy outcomes occurred in 44.5%, including prematurity (34.4%), low birth weight (19.3%), and fetal distress (12.9%). Compared with women with good outcomes, those with poor outcomes had significantly lower RBCF (255.61 ± 51.56 vs 310.45 ± 53.13 ng/mL, p < 0.001) and higher Hcy (9.04 ± 1.36 vs 7.90 ± 1.25 μmol/L, p < 0.001). ROC analysis showed that combined RBCF-Hcy testing provided the highest predictive performance for adverse outcomes (AUC = 0.85, 95% CI 0.81-0.89; sensitivity 85.52%; specificity 75.14%), outperforming either biomarker alone. Conclusion: RBCF and Hcy are crucial biomarkers for assessing the severity of HDCP and predicting adverse pregnancy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.